ARM YOURSELF WITH THE PROPEL FAMILY OF IMPLANTS, AN INNOVATION IN SINUS TECHNOLOGY
PROPEL is the FIRST and ONLY PMA-approved steroid-eluting sinus implant4
OPENS + DELIVERS
PROPEL keeps the sinuses open while releasing MF
PROPEL implants feature an innovative 2-in-1 mechanism that opens the sinuses while delivering mometasone furoate (MF), a potent corticosteroid, directly where it is needed1-3
+OPENS the sinus cavity
-
Self-expanding design that opens and supports the sinus cavity1
-
Non-obstructive design allows for sinus mucociliary clearance and the delivery of topical rinses1
-
Dissolvable frame bio-absorbs over 30-45 days after placement as the sinus cavity heals11
Mometasone furoate delivers the ideal combination of potency and safety
Drug characteristics comparison6-9
Topical Corticosteroid |
Lipophilicity6* |
Potency7† (Receptor Affinity) |
Systemic Bioavailability8‡ |
Dexamethasone |
Very Low (<1.0)9 |
Very Low (100) |
High (76%) |
Triamcinolone (Kenalog) |
Low (1.0) |
Low (233) |
Medium (46%) |
Budesonide |
Low (1.6) |
Intermediate (935) |
Medium (34%) |
Mometasone furoate |
High (20.0) |
High (2300) |
Very Low (<1%) |
Mometasone furoate was selected for use in PROPEL implants for its optimal sinonasal drug characteristics10:
Highly lipophilic
Readily absorbs into tissue
Low systemic bioavailability
Minimizes systemic effects
PROPEL implants are clinically proven to maintain patency and improve patient outcomes following ESS by targeting inflammation, the underlying cause of chronic rhinosinusitis
YOUR PATIENT
+
PROPEL
=
IMPROVED
OUTCOMES